These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2095462)

  • 1. [HIV infection. The biological mechanism].
    Boschini A
    Riv Odontoiatr Amici Brugg; 1990; 9(4):25-8, 30-2. PubMed ID: 2095462
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.
    Tyler DS; Stanley SD; Nastala CA; Austin AA; Bartlett JA; Stine KC; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1990 May; 144(9):3375-84. PubMed ID: 2329275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics of rapid progressors in HIV infection].
    Khanlou H; Salmon-Ceron D; Sicard D
    Ann Med Interne (Paris); 1997; 148(2):163-6. PubMed ID: 9238442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific immunity to HIV and other retroviral infections.
    Gorny MK; Pinter A; Zolla-Pazner S
    Prog AIDS Pathol; 1989; 1():181-99. PubMed ID: 2562356
    [No Abstract]   [Full Text] [Related]  

  • 5. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women.
    Hirbod T; Broliden K
    J Intern Med; 2007 Jul; 262(1):44-58. PubMed ID: 17598814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immunity to HIV-1: neutralization and beyond.
    Huber M; Trkola A
    J Intern Med; 2007 Jul; 262(1):5-25. PubMed ID: 17598812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and laboratory characteristics of HIV-infection in servicemen].
    Volzhanin VM; Zigalenko DG; Bolekhan VN; Bulan'kov IuI; Chabanenko AI
    Voen Med Zh; 2005 Jan; 326(1):47-52, 80. PubMed ID: 15754771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR; Gray CM; Cox JH; Ferrari G
    Expert Rev Vaccines; 2006 Aug; 5(4):505-16. PubMed ID: 16989631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 10. The immune response to HIV: implications for vaccine development.
    Bolognesi DP
    Semin Immunol; 1993 Jun; 5(3):203-14. PubMed ID: 8347841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of immune responses during HIV-malaria co-infection in pregnancy.
    Ned RM; Moore JM; Chaisavaneeyakorn S; Udhayakumar V
    Trends Parasitol; 2005 Jun; 21(6):284-91. PubMed ID: 15922250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antituberculosis humoral immunity in patients with tuberculosis, HIV infection concurrent with tuberculoses].
    Khaertynova IM; Tsybul'kin AP; Valiev RSh; Idiiatullina GA; Romanenko SE
    Probl Tuberk Bolezn Legk; 2009; (5):44-8. PubMed ID: 19565814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.
    Pantaleo G; Koup RA
    Nat Med; 2004 Aug; 10(8):806-10. PubMed ID: 15286782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the future of HIV vaccines.
    Nabel GJ
    Nat Rev Microbiol; 2007 Jul; 5(7):482-4. PubMed ID: 17571457
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV pathogenesis: 25 years of progress and persistent challenges.
    Levy JA
    AIDS; 2009 Jan; 23(2):147-60. PubMed ID: 19098484
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative study on some systemic humoral and cellular immune markers in only HIV or HIV and hepatitis B infected children.
    Voiculescu C; Bălăşoiu M; Turculeanu A; Filipaş L; Voiculescu M; Georgescu D
    Rev Roum Virol; 1993; 44(1-2):97-111. PubMed ID: 8043485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.
    Mestecky J
    J Reprod Immunol; 2006 Dec; 72(1-2):1-17. PubMed ID: 17095369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection.
    Williams SB; Flanigan TP; Artenstein AW; VanCott TC; Smith D; Mayer K; Koup RA
    J Infect Dis; 1999 May; 179(5):1310-2. PubMed ID: 10191415
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.